Welcome to the Celgene REMS Program

To avoid embry-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the Celgene products THALOMID® (thalidomide), REVLIMID® (lenalidomide) and POMALYST® (pomalidomide). The THALOMID REMS® program, REVLIMID REMS® program, and POMALYST REMS® program require prescribers and pharmacists to be certified and patients to enroll and comply with all of the requirements for each program.

If you would like to obtain more information about any of the Celgene REMS programs, please click on the program name below:

- **RevlimidREMS®**
  Visit [www.REVlimidREMs.com](http://www.REVlimidREMs.com), to learn more about the RevlimidREMS® program.

- **PomalySTREMS®**
  Visit [www.POMALystREMS.com](http://www.POMALystREMS.com), to learn more about the POMALystREMS® program.

- **THALOMIDREMS®**
  Visit [www.THALOMidREMS.com](http://www.THALOMidREMS.com), to learn more about the THALOMIDREMS® program.

For prescribers, please enter your User Name and Password to manage your patients through a Celgene REMS program. If you do not have an online account, please select Create User Account to establish an account. Patients currently enrolled in a Celgene REMS program are not required to create an online account to complete a survey. Please select Patient Surveys and enter the information requested to begin a survey.

To login to your account:

- User Name
- Password

Forgot Password? [Login]
Home Page (after prescriber logon)

Click on a button below to access the corresponding REMS menu of operations for that product: enroll a patient, access an existing or save a new Patient-Physician Agreement Form, complete a prescriber survey or write a prescription.

For REVLIMID REMS®

RevlimidREMS®

Please see full Prescribing Information, including: Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

Visit www.REVLI midREMS.com to learn more about the REVLIMID REMS® program.

For POMALYST REMS®

PomalystREMS®

Please see full Prescribing Information, including: Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

Visit www.POMALYSTREMS.com to learn more about the POMALYST REMS® program.

For THALOMID REMS®

THALOMIDREMS®

Please see full Prescribing Information, including: Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

Visit www.THALOMIDREMS.com to learn more about the THALOMID REMS® program.

The Prescriber Dashboard is an optional resource that displays the status of patients under your care for a specific Celgene REMS program. A patient search function is also included to access detailed patient history information.

Select the “Manage My Account” button to view your Celgene REMS online account information.
REVLIMID REMS module
Welcome to the REVLIMID REMS® program

REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).

REVLIMID is indicated as maintenance therapy in patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).

REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

Important information about REVLIMID and the REVLIMID Risk Evaluation and Mitigation Strategy (REMS) program

- REVLIMID is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with REVLIMID provided adequate precautions are taken to avoid pregnancy.
- To avoid embryo-fetal exposure, REVLIMID is only available under a restricted distribution program called “REVLIMID REMS”.
- Only prescribers and pharmacies certified by the REVLIMID REMS program can prescribe and dispense REVLIMID to patients who are enrolled and meet all the conditions of the REVLIMID REMS program.

The goals of the REVLIMID risk evaluation and mitigation strategy are as follows:
1. To prevent the risk of embryo-fetal exposure to REVLIMID.
2. To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for REVLIMID.
About the REVLIMID REMS® program

REVLIMID® (thalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).

REVLIMID is indicated as maintenance therapy in patients with MM following autologous hematopoietic stem cell transplantation (SCT).

REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to beta- or intermediate-1-thalassemia.

REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bendamustine.

To avoid embryo-fetal exposure, REVLIMID is only available under a restricted distribution program called REV-LIMID Risk Evaluation and Mitigation Strategy (REMS). Only certified prescribers can prescribe REVLIMID and only certified pharmacies can dispense REVLIMID in the REV-LIMID REMS program.

In order to receive REVLIMID, all patients must be enrolled in the REV-LIMID REMS program and agree to comply with the requirements of the REV-LIMID REMS program.

Key points of the REV-LIMID REMS® program

Prescriber

- The prescriber enrolls and becomes certified with Celgene for the REV-LIMID® REMS® program.
- The prescriber counsels patient on benefits and risks of REV-LIMID.
- The prescriber provides contraception and emergency contraception counseling.
- The prescriber verifies negative pregnancy test for all female patients of reproductive potential.
- The prescriber completes a REV-LIMID® (remallidomide) Patient-Physician Agreement Form with each patient and sends to Celgene.
- The prescriber or the pharmacist completes applicable mandatory confirmatory survey.
- The prescriber obtains an authorization number from Celgene and writes it on every prescription, along with the patient's risk category.
- The prescriber writes no more than a 4-week (28-days supply, either automatic refill or telephone prescriptions)
- The prescriber sends a REV-LIMID prescription to certified pharmacy.

Pharmacy

- The pharmacy verifies patient eligibility for REV-LIMID REMS program.
- The pharmacy must retain a copy of the patient's consent form.
- The pharmacy verifies the patient's pregnancy status.
- The pharmacy must complete the Education and Counseling Checklist.
- The pharmacy dispenses REVLIMID to patient along with a Medication Guide.

Privacy policy | Terms of Use | Site map | Contact us

REV-LIMID® and REV-LIMID® REMS are registered trademarks of Celgene Corporation.
© 2013, Celgene Corporation. www.celgene.com
This website is intended for residents of the United States only.